全文获取类型
收费全文 | 903篇 |
免费 | 58篇 |
国内免费 | 47篇 |
出版年
2024年 | 2篇 |
2023年 | 32篇 |
2022年 | 63篇 |
2021年 | 62篇 |
2020年 | 38篇 |
2019年 | 44篇 |
2018年 | 38篇 |
2017年 | 25篇 |
2016年 | 26篇 |
2015年 | 28篇 |
2014年 | 65篇 |
2013年 | 68篇 |
2012年 | 29篇 |
2011年 | 30篇 |
2010年 | 34篇 |
2009年 | 38篇 |
2008年 | 40篇 |
2007年 | 25篇 |
2006年 | 34篇 |
2005年 | 29篇 |
2004年 | 22篇 |
2003年 | 20篇 |
2002年 | 26篇 |
2001年 | 10篇 |
2000年 | 17篇 |
1999年 | 9篇 |
1998年 | 11篇 |
1997年 | 3篇 |
1996年 | 6篇 |
1995年 | 7篇 |
1994年 | 12篇 |
1993年 | 14篇 |
1992年 | 11篇 |
1991年 | 6篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 6篇 |
1985年 | 7篇 |
1984年 | 10篇 |
1983年 | 5篇 |
1982年 | 4篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1979年 | 4篇 |
1978年 | 6篇 |
1976年 | 4篇 |
1975年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有1008条查询结果,搜索用时 78 毫秒
941.
《American journal of human genetics》2022,109(4):618-630
Pathogenic variants in BRCA1 are associated with a greatly increased risk of hereditary breast and ovarian cancer (HBOC). With the increased availability and affordability of genetic testing, many individuals have been identified with BRCA1 variants of uncertain significance (VUSs), which are individually detected in the population too infrequently to ascertain a clinical risk. Functional assays can be used to experimentally assess the effects of these variants. In this study, we used multiplexed DNA repair assays of variants in the BRCA1 carboxyl terminus to functionally characterize 2,271 variants for homology-directed repair function (HDR) and 1,427 variants for cisplatin resistance (CR). We found a high level of consistent results (Pearson’s r = 0.74) in the two multiplexed functional assays with non-functional variants located within regions of the BRCA1 protein necessary for its tumor suppression activity. In addition, functional categorizations of variants tested in the multiplex HDR and CR assays correlated with known clinical significance and with other functional assays for BRCA1 (Pearson’s r = 0.53 to 0.71). The results of the multiplex HDR and CR assays are useful resources for characterizing large numbers of BRCA1 VUSs. 相似文献
942.
《Cell host & microbe》2022,30(1):53-68.e12
- Download : Download high-res image (234KB)
- Download : Download full-size image
943.
944.
《Cell reports》2023,42(8):112896
- Download : Download high-res image (230KB)
- Download : Download full-size image
945.
946.
Random genetic mutations, which can occur during cell line development, can lead to sequence variants that comprise pharmaceutical product quality generated by recombinant technology. Mutation screening can minimize the probability of selecting clones harboring sequence variants. Here we report a polymerase chain reaction (PCR)-based mutation screening approach using high-resolution melting (HRM) analysis combined with a mutation enrichment step using limiting dilution to detect low-level mutations at 0.5%. The method allows unknown mutation discovery regardless of its location in a transgene as well as independent of its position in an HRM fragment, ranging from approximately 200 to 300 bp in size. 相似文献
947.
T. Ren W. Li D. Liu K. Liang X. Wang H. Li R. Jiang Y. Tian X. Kang Z. Li 《Animal genetics》2019,50(3):279-282
Glutaminyl‐peptide cyclotransferase‐like (QPCTL) is an isoenzyme of glutaminyl‐peptide cyclotransferase (QPCT). QPCTL and QPCT catalyze the formation of N‐terminal modified pyroglutamate‐fractalkine and the chemokine CCL2. The objective of this study was to investigate the association between insertions/deletions in the chicken QPCTL promoter region with growth traits in chickens. We first detected two insertion/deletion variants of QPCTL via whole‐genome resequencing analysis of DNA samples from Xichuan chickens. A total of 1896 individuals from 12 breeds were genotyped for 52‐ and 224‐bp insertions/deletions. We found two novel insertions/deletions in the promoter region of the chicken QPCTL gene and studied their association with chicken body weight and carcass traits. Our findings show that QPCTL can be a molecular marker for chicken genetics and breeding programs. 相似文献
948.
949.
Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell
Natural killer (NK) cells are an important subset of lymphocytes which play a critical role in host immunity against cancers. With MHC-independent recognition, short lifespan and potent cytotoxicity, NK cells make a promising candidate for chimeric antigen receptor (CAR)-engineered cancer immunotherapy. Due to innate biological properties of NK cells, CAR-NK may outperform CAR-T therapy in terms of less side effects and more universal access, which may become a great reformation in CAR-based cancer immunotherapy. The CARs used in peripheral blood (PB) NK cells as well as NK cell line like NK-92 are the most important outfits defining antigenic specificity. The constructs of CARs used in NK cells from different sources vary, which all undergo generational optimization. The anti-tumor effects of CAR-NK have been validated in numerous preclinical trials for cancers, including hematologic malignancies and many solid tumors, which provide evidence for potential clinical application of CAR-NK. Additionally, this review concludes the challenges faced in the application of CAR-NK. Although CAR-NK is considered as one of the most possible “off-the-shelf” products, the improvement for the efficiency of expansion and transduction as well as the solution for underlying safety issues is still needed. Possible coping strategies for challenges and upgrades in techniques are also highlighted for future development in CAR-NK cancer immunotherapy. 相似文献
950.